MX2012002427A - Anticuerpos anticina que se unen a quimiocinas cc multiples. - Google Patents
Anticuerpos anticina que se unen a quimiocinas cc multiples.Info
- Publication number
- MX2012002427A MX2012002427A MX2012002427A MX2012002427A MX2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A MX 2012002427 A MX2012002427 A MX 2012002427A
- Authority
- MX
- Mexico
- Prior art keywords
- chemokines
- antikine
- bind
- antikine antibodies
- antibodies
- Prior art date
Links
- 108010040471 CC Chemokines Proteins 0.000 title abstract 2
- 102000001902 CC Chemokines Human genes 0.000 title abstract 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 abstract 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 abstract 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 abstract 1
- 108010055166 Chemokine CCL5 Proteins 0.000 abstract 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 abstract 1
- 101000577064 Lymnaea stagnalis Molluscan insulin-related peptide 1 Proteins 0.000 abstract 1
- -1 MIP-lα/CCL3 Proteins 0.000 abstract 1
- 101000737895 Mytilus edulis Contraction-inhibiting peptide 1 Proteins 0.000 abstract 1
- 230000009824 affinity maturation Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Rehabilitation Therapy (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23801509P | 2009-08-28 | 2009-08-28 | |
| PCT/US2010/047004 WO2011025962A1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002427A true MX2012002427A (es) | 2012-08-03 |
Family
ID=43628404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002427A MX2012002427A (es) | 2009-08-28 | 2010-08-27 | Anticuerpos anticina que se unen a quimiocinas cc multiples. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US8313747B2 (enExample) |
| EP (1) | EP2470671B1 (enExample) |
| JP (2) | JP6109571B2 (enExample) |
| KR (1) | KR101778813B1 (enExample) |
| CN (1) | CN102782148B (enExample) |
| AU (1) | AU2010286516B2 (enExample) |
| BR (1) | BR112012004387A2 (enExample) |
| CA (1) | CA2771781C (enExample) |
| DK (1) | DK2470671T3 (enExample) |
| ES (1) | ES2531561T3 (enExample) |
| HR (1) | HRP20150162T1 (enExample) |
| IN (1) | IN2012DN01769A (enExample) |
| MX (1) | MX2012002427A (enExample) |
| PL (1) | PL2470671T3 (enExample) |
| PT (1) | PT2470671E (enExample) |
| SI (1) | SI2470671T1 (enExample) |
| SM (1) | SMT201500011B (enExample) |
| WO (1) | WO2011025962A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2470671T3 (pl) * | 2009-08-28 | 2015-05-29 | Regeneron Pharma | Przeciwciała antykinowe wiążące się z wieloma chemokinami CC |
| DK2717941T3 (da) * | 2011-06-13 | 2020-07-13 | Tla Targeted Immunotherapies Ab | Behandling af cancer |
| WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
| EP2763540A4 (en) * | 2011-09-09 | 2015-04-22 | Univ Yale | COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES |
| MY181648A (en) | 2012-08-24 | 2020-12-30 | Univ California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
| TWI612059B (zh) * | 2013-03-15 | 2018-01-21 | 美國禮來大藥廠 | 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體 |
| CN105358175B (zh) | 2013-05-23 | 2020-10-16 | 夏尔人类遗传性治疗公司 | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 |
| JP6220222B2 (ja) * | 2013-10-28 | 2017-10-25 | シスメックス株式会社 | 関節リウマチの診断を補助するための方法、システム及びコンピュータプログラム製品 |
| CN114044825A (zh) * | 2013-12-09 | 2022-02-15 | 爱乐科斯公司 | 抗Siglec-8抗体及其使用方法 |
| AU2015222757B2 (en) | 2014-02-28 | 2020-10-08 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
| WO2015132790A2 (en) | 2014-03-04 | 2015-09-11 | Chemomab Ltd. | Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines |
| CN104198727A (zh) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | 人血清ccl2酶联免疫检测试剂盒及其制备和使用方法 |
| TWI566780B (zh) * | 2014-10-24 | 2017-01-21 | 國立陽明大學 | 巨噬細胞發炎蛋白－１β（ＭＩＰ－１β）抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途 |
| SMT202400313T1 (it) | 2014-12-09 | 2024-09-16 | Regeneron Pharma | Animali non umani aventi un cluster umanizzato di un gene di differenziazione 274 |
| EP3310385A4 (en) | 2015-06-17 | 2018-12-19 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| JP2020513554A (ja) | 2016-12-07 | 2020-05-14 | プロジェニティ， インコーポレイテッド | 胃腸管の検出方法、装置およびシステム |
| WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| JP7122002B2 (ja) | 2017-03-01 | 2022-08-19 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
| RU2740438C1 (ru) * | 2017-04-05 | 2021-01-14 | Корея Рисерч Инститьют Оф Байосайенс Энд Байотекнолоджи | Активирующий nk-клетки слитый белок, nk-клетки и фармацевтическая композиция, включающая их |
| MX2019013137A (es) | 2017-05-05 | 2020-07-14 | Allakos Inc | Metodos y composiciones para tratar enfermedades oculares alergicas. |
| WO2019037067A1 (zh) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | 巨噬细胞发炎蛋白-1β(MIP-1β)抑制剂用以治疗及控管动脉粥状硬化的用途 |
| JP7543135B2 (ja) * | 2017-10-13 | 2024-09-02 | エー アンド ジー ファーマシューティカル，インコーポレイテッド | プロスタグランジンｆ２受容体阻害剤に対するモノクローナル抗体及びコンジュゲート、並びにそれらの使用 |
| WO2019133902A2 (en) * | 2017-12-28 | 2019-07-04 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
| WO2019165397A1 (en) * | 2018-02-26 | 2019-08-29 | Cornell University | Quantitative biomarkers of ehv-1 susceptibility and protection |
| EP3791187A4 (en) * | 2018-05-11 | 2022-01-12 | Halcyon Therapeutics, Inc. | BINDING PROTEINS AND CHIMERIC ANTIGEN RECEPTOR T-CELLS AGAINST GASP-1 GRANULES AND THEIR USE |
| CA3120619A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN110117329B (zh) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | 包含趋化因子与结合伴侣的融合多肽及其用途 |
| KR102489282B1 (ko) * | 2019-07-02 | 2023-01-17 | 고려대학교 산학협력단 | Ccl4, ccl5, ccl20, 및 ccl21을 유효성분으로 포함하는 임신촉진용 조성물 |
| EP3994167A4 (en) * | 2019-07-02 | 2023-11-01 | Astute Medical, Inc. | ANTIBODIES AND ASSAY FOR CCL14 |
| EP4309722A3 (en) | 2019-12-13 | 2024-08-07 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN113893331B (zh) * | 2020-07-06 | 2024-11-26 | 中国农业科学院特产研究所 | 一种诱导母鹿生茸的产品及其制备方法和诱导母鹿生茸的方法和应用 |
| WO2022011110A2 (en) * | 2020-07-08 | 2022-01-13 | Georgia Tech Research Corporation | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection |
| PE20231859A1 (es) * | 2020-10-16 | 2023-11-21 | Lanova Medicines Ltd | Anticuerpos monoclonales anti-ccr8 y sus usos |
| CN115598111B (zh) * | 2021-07-08 | 2025-03-25 | 南京大学 | 基于邻位诱导免疫分析的特异性杂交瘤细胞化学发光筛选方法 |
| CN114990073A (zh) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | 一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| NZ255101A (en) * | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
| US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
| US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
| US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| AU2003265575B2 (en) | 2002-08-19 | 2009-12-10 | Astrazeneca Ab | Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof |
| CA2507080C (en) | 2002-11-27 | 2015-01-06 | Biogen Idec Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
| AU2005318173B2 (en) * | 2004-12-21 | 2011-05-12 | Merck Serono Sa | CC-chemokine antagonists |
| DK2185719T3 (en) * | 2007-08-02 | 2014-02-17 | Novimmune Sa | ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF |
| PL2470671T3 (pl) * | 2009-08-28 | 2015-05-29 | Regeneron Pharma | Przeciwciała antykinowe wiążące się z wieloma chemokinami CC |
-
2010
- 2010-08-27 PL PL10812667T patent/PL2470671T3/pl unknown
- 2010-08-27 AU AU2010286516A patent/AU2010286516B2/en active Active
- 2010-08-27 DK DK10812667T patent/DK2470671T3/en active
- 2010-08-27 US US12/870,573 patent/US8313747B2/en active Active
- 2010-08-27 PT PT10812667T patent/PT2470671E/pt unknown
- 2010-08-27 BR BR112012004387A patent/BR112012004387A2/pt active Search and Examination
- 2010-08-27 HR HRP20150162TT patent/HRP20150162T1/hr unknown
- 2010-08-27 SI SI201030901T patent/SI2470671T1/sl unknown
- 2010-08-27 KR KR1020127007885A patent/KR101778813B1/ko not_active Expired - Fee Related
- 2010-08-27 CA CA2771781A patent/CA2771781C/en active Active
- 2010-08-27 JP JP2012527033A patent/JP6109571B2/ja active Active
- 2010-08-27 CN CN201080048961.XA patent/CN102782148B/zh not_active Expired - Fee Related
- 2010-08-27 EP EP20100812667 patent/EP2470671B1/en active Active
- 2010-08-27 IN IN1769DEN2012 patent/IN2012DN01769A/en unknown
- 2010-08-27 ES ES10812667.3T patent/ES2531561T3/es active Active
- 2010-08-27 MX MX2012002427A patent/MX2012002427A/es active IP Right Grant
- 2010-08-27 WO PCT/US2010/047004 patent/WO2011025962A1/en not_active Ceased
-
2012
- 2012-10-22 US US13/657,120 patent/US9005617B2/en active Active
-
2015
- 2015-01-16 SM SM201500011T patent/SMT201500011B/xx unknown
- 2015-02-24 US US14/630,112 patent/US20150166647A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011829A patent/JP2016135783A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011025962A1 (en) | 2011-03-03 |
| IN2012DN01769A (enExample) | 2015-06-05 |
| HRP20150162T1 (hr) | 2015-05-08 |
| CA2771781A1 (en) | 2011-03-03 |
| US9005617B2 (en) | 2015-04-14 |
| JP2013503192A (ja) | 2013-01-31 |
| JP6109571B2 (ja) | 2017-04-05 |
| CN102782148B (zh) | 2016-04-20 |
| CA2771781C (en) | 2019-01-15 |
| US20130108640A1 (en) | 2013-05-02 |
| EP2470671B1 (en) | 2014-12-24 |
| US20150166647A1 (en) | 2015-06-18 |
| KR20120091013A (ko) | 2012-08-17 |
| PL2470671T3 (pl) | 2015-05-29 |
| ES2531561T3 (es) | 2015-03-17 |
| KR101778813B1 (ko) | 2017-09-14 |
| SI2470671T1 (sl) | 2015-04-30 |
| US20110059107A1 (en) | 2011-03-10 |
| PT2470671E (pt) | 2015-02-05 |
| JP2016135783A (ja) | 2016-07-28 |
| BR112012004387A2 (pt) | 2015-09-08 |
| AU2010286516B2 (en) | 2016-10-06 |
| SMT201500011B (it) | 2015-03-05 |
| DK2470671T3 (en) | 2015-02-09 |
| EP2470671A1 (en) | 2012-07-04 |
| AU2010286516A2 (en) | 2012-06-14 |
| US8313747B2 (en) | 2012-11-20 |
| AU2010286516A1 (en) | 2012-03-08 |
| EP2470671A4 (en) | 2013-04-03 |
| RU2012111820A (ru) | 2013-10-10 |
| CN102782148A (zh) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012002427A (es) | Anticuerpos anticina que se unen a quimiocinas cc multiples. | |
| TN2014000107A1 (en) | Anti-aplhabetatcr antibody | |
| MX2010007935A (es) | Anticuerpo monoclonal humanizado anti-nkg2a humano. | |
| PH12018500635A1 (en) | Bispecific antibodies specific for pd1 and tim3 | |
| EP4477668A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| MX2009008608A (es) | Anticuerpos monoclonales anti-cxcl13. | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| NZ602176A (en) | Cd37-binding molecules and immunoconjugates thereof | |
| MX2019001355A (es) | Anticuerpos monoclonales multiespecíficos. | |
| WO2015173756A3 (en) | Bispecific antibodies with engineered ch1-cl interfaces | |
| UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
| CR20190009A (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso. | |
| MX337684B (es) | Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f. | |
| TN2013000292A1 (en) | Antibody molecules which bind il-17a and il-17f | |
| MX2012000841A (es) | Optimizacion de la produccion de anticuerpos. | |
| WO2013177101A3 (en) | Il-17a/f il-23 bispecific antibodies and their uses | |
| WO2009130459A3 (en) | Epitopes of il-17a and il-17f and antibodies specific thereto | |
| MX2014002996A (es) | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. | |
| WO2013186630A3 (en) | Humanized antibodies to ca215 | |
| WO2012122513A3 (en) | Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution | |
| CY1116009T1 (el) | Αντισωματα αντικινες που προσδενονται σε πολλαπλες χημειοκινες cc | |
| AU2016219622A1 (en) | Heterodimeric antibody FC-containing proteins and methods for production thereof | |
| NZ779866A (en) | Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use | |
| TN2013000186A1 (en) | Anti-il-23 antibodies | |
| EA201990353A1 (ru) | АНТИТЕЛА, ОБЛАДАЮЩИЕ СПОСОБНОСТЬЮ НЕЙТРАЛИЗОВАТЬ ГЛАВНЫЕ ЭКЗОТОКСИНЫ TcdA И TcdB Clostridium difficile |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or assignment |
Owner name: REGENERON PHARMACEUTICALS, INC. |
|
| FG | Grant or registration |